KRAS mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer

被引：0
|
作者：
Di Fiore, F. [1 ]
Le Pessot, F. [1 ]
Lamy, A. [1 ]
Charbonnier, F. [1 ]
Sabourin, J. [1 ]
Paillot, B. [1 ]
Frebourg, T. [1 ]
Michel, P. [1 ]
机构：
[1] Rouen Univ Hosp, INSERM, U 614, Rouen, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10502
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Development of an assay for KRAS mutation as a predictive marker for cetuximab in colorectal cancer
    Yokota, T.
    Muro, K.
    Shibata, N.
    Ura, T.
    Takahari, D.
    Shitara, K.
    Yatabe, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Lièvre, A
    Bachet, JB
    Le Corre, D
    Boige, V
    Landi, B
    Emile, JF
    Côté, JF
    Tomasic, G
    Penna, C
    Ducreux, M
    Rougier, P
    Penault-Llorca, F
    Laurent-Puig, P
    CANCER RESEARCH, 2006, 66 (08) : 3992 - 3995
  • [3] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Lievre, A.
    Bachet, J.
    Boige, V
    Landi, B.
    Emile, J.
    Cote, J.
    Tomasic, G.
    Rougier, P.
    Penault-Llorca, F.
    Laurent-Puig, P.
    ANNALS OF ONCOLOGY, 2006, 17 : 42 - 42
  • [4] Commentary on "KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer"
    Benjamin, Laura E.
    CANCER RESEARCH, 2016, 76 (15) : 4309 - 4310
  • [5] Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
    Ucar, Gokhan
    Ergun, Yakup
    Esen, Selin Akturk
    Acikgoz, Yusuf
    Dirikoc, Merve
    Esen, Irfan
    Bal, Oznur
    Uncu, Dogan
    MEDICINE, 2020, 99 (39) : E22407
  • [6] Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
    Hsu, Hung-Chih
    Thiam, Tan Kien
    Lu, Yen-Jung
    Yeh, Chien Yuh
    Tsai, Wen-Sy
    You, Jeng Fu
    Hung, Hsin Yuan
    Tsai, Chi-Neu
    Hsu, An
    Chen, Hua-Chien
    Chen, Shu-Jen
    Yang, Tsai Sheng
    ONCOTARGET, 2016, 7 (16) : 22257 - 22270
  • [7] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
    F Di Fiore
    F Blanchard
    F Charbonnier
    F Le Pessot
    A Lamy
    M P Galais
    L Bastit
    A Killian
    R Sesboüé
    J J Tuech
    A M Queuniet
    B Paillot
    J C Sabourin
    F Michot
    P Michel
    T Frebourg
    British Journal of Cancer, 2007, 96 : 1166 - 1169
  • [8] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
    Di Fiore, F.
    Blanchard, F.
    Charbonnier, F.
    Le Pessot, F.
    Lamy, A.
    Galais, M. P.
    Bastit, L.
    Killian, A.
    Sesboue, R.
    Tuech, J. J.
    Queuniet, A. M.
    Paillot, B.
    Sabourin, J. C.
    Michot, F.
    Michel, P.
    Frebourg, T.
    BRITISH JOURNAL OF CANCER, 2007, 96 (08) : 1166 - 1169
  • [9] KRAS mutation testing in metastatic colorectal cancer
    Cong Tan
    World Journal of Gastroenterology, 2012, (37) : 5171 - 5180
  • [10] KRAS mutation testing in metastatic colorectal cancer
    Tan, Cong
    Du, Xiang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (37) : 5171 - 5180
12345